New drug combo aims to boost myeloma treatment
NCT ID NCT05002816
First seen Nov 01, 2025 · Last updated Jun 22, 2026 · Updated 38 times
Summary
This study tests whether combining two approved drugs, belantamab mafodotin and elotuzumab, is safe and works better than either alone for multiple myeloma. About 24 adults whose cancer has returned or not responded to at least three prior treatments will receive the combination. The goal is to find the best dose and see if it improves response rates.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Yale New Haven Hospital
New Haven, Connecticut, 06512, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
belantamab mafodotin and elotuzumab
What this could lead to
If it works, this could offer a new, more effective treatment option for people with multiple myeloma who have not responded to other therapies.
What could go wrong
This is an early-phase trial with only 24 participants, so results may not apply to everyone. The drug combination may cause serious side effects, including eye problems and low blood counts.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.